November 2022 FDA Recall Daytrana by Noven Pharmaceuticals Inc
D-0071-2023 - Defective Delivery System

This Class II drug recall was voluntarily initiated by Noven Pharmaceuticals Inc on November 16, 2022 for the product Daytrana. The FDA reported the reason for recall as defective delivery system. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0071-2023

Reason for Recall
Defective Delivery System: Recalled lot was found to be out of specification for shear. Shear is an attribute related to the adhesive properties of the transdermal patches.
Initiated
11-16-2022
Reported
12-07-2022
Quantity
3977 boxes

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Noven Pharmaceuticals Inc
Nationwide in the USA
Daytrana (methylphenidate transdermal system), Delivers 15 mg over 9 hours, (1.6 mg/hr), 30 patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186; By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC 68968-5553-3.

Batch or Lot Expiration Information

Lot# Lot: 91316 Exp. 02/2023